2 hours 56 minutes ago - Standard & Poor's
Q4 net loss of $0.41, vs. $0.46, is $0.01 wider than our loss view. Benlysta sales of $25.7M is in line with HGSI's pre-announcement. Although we see limited visibility into Benlysta sales ramp trajectory, we are encouraged by report of positive physician feedback on drug and by HGSI re-affirming profitability target for '14. We expect Benlysta use to expand over time amid lack of lupus options. On narrower Benlysta sales outlook, we widen our '12 loss estimate $0.11 to $1.38, and set '13's at $0.92 loss. On revised forward P/E analysis, we trim our target price to $13.
HGSI is priced right for gains,see you guys over 10 soon and with buy outs in the sector heating up,hgsi could be a morning halt and major gapper anytime.IMO
All my posts are my opinions. Investors should do there own DD!!
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM